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Antipsychotic Drug Use: Managing Cardiometabolic and Cost Effects

Introduction
Across the US, 30%, or approximately one third of people meet the criteria for at
least one mental illness.1 Of those with severe mental illness (SMI), namely schizophrenia
and bipolar disorder, the mortality rate is more than twofold compared to the general
population.2 The cardiovascular risk factors that contribute to cardiovascular related
deaths, including metabolic disease and type II diabetes, are not only modifiable, but
staggeringly higher for those with SMI.3 Though antipsychotic drug prescription is the
standard protocol for SMI treatment, such drug effects on cardiovascular risk factors
and related deaths exacerbate the much higher mortality rate for the severely mentally
ill population. Due to both the prevalence of SMI and the physical comorbidities that it
entails, analysis of healthcare costs associated with this population are an essential part
of general health and policy improvement for the U.S. Therefore, a breakdown of the
healthcare costs of this population requires not only acknowledgment of the modes of
treatment for mental illness specifically, but also the identification and cost-analysis of
the commonly associated physical comorbidities. This is especially important
considering SMI is almost always considered chronic, and many SMI patients qualify for
either Medicare, Medicaid, or both. Certain gaps in coverage can lead to lack of
preventive care, exacerbating the cost burden.4
From a clinician’s perspective, assessing relevant scientific studies and reviews to
change the relationship between primary care and psychiatry is necessary to dampen
the high mortality rate of the SMI population.
From a policy-maker’s perspective, analyzing the cause and effect balance
between managing costs of care directed at the SMI itself against the adjunct costs
from physical comorbidity calls for a change in the structure of therapeutic care and
how the SMI population accesses primary care.
The Collaborative Care model is a health care model that unifies psychiatric,
behavioral, and primary care to support the mental, behavioral, and physical health of
patients. By supporting holistic healthcare, the high cost of care for the SMI population
will be diminished. The model includes four parts: patient-centered care, populationbased care, measurement-based treatment to target, and evidence-based care.
Swapping oral antipsychotics with injectable versions will be especially cost-effective by
improving adherence rates, and thus, reducing institutionalization and other
hospitalizations. By enforcing the Collaborative Care model through community health
center interventions, clinicians and policy makers will be able to work together to
effectively leverage the health of the SMI population while eroding the high health
care expenditure that this population currently imposes on states.
1 Marth Ward and Ann Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," Journal of
Hospital Medicine 8, no. 9 (2013): 523,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=90096361&site=ehost-live.
2 Kai G. Kahl, Mechthild Westhoff-Bleck, and Tillmann H. C. Krüger, "Effects of Psychopharmacological Treatment with Antidepressants on the
Vascular System," Vascular Pharmacology 96, (2017): 11,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=125141989&site=ehost-live.
3 John W. Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," The
Journal of Clinical Psychiatry 70 Suppl 3 (2009): 30-31, http://search
.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=19570499&site=ehost-live.
4 Linda Simoni-Wastila, Ilene H. Zuckerman, Thomas Shaffer, Christopher M. Blanchette, and Bruce Stuart, "Drug use Patterns in Severely Mentally Ill
Medicare Beneficiaries: Impact of Discontinuities in Drug Coverage," Health Services Research 43, no. 2 (2008): 504,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=31424857&site=ehost-live.
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What is SMI?
Severe mental illness, or SMI, represents a select group of diagnoses in the
mentally ill population. These SMIs have similarities in their presentation and are
oftentimes treated with the same types of psychotropic drugs. Researchers consistently
use the label SMI to refer to mental illnesses characterized by psychosis or related
episodes; episodes of psychosis are indicative of a break from reality, often in the form
of hallucinations or delusions. The two diagnoses that most commonly encompass SMI
are schizophrenia and bipolar disorder.5
Higher Morbidity through Physical Illness
Morbidity refers to the presence of disease. Multiple clinical studies across various
countries have established that those with SMI suffer significantly greater morbidity than
the general population.6 While some may assume that the leading cause of death for
SMI patients is from the mental illness itself, physical impairments are at the forefront,
leading to acute cardiovascular events such as heart attack and stroke.7 In fact, for the
mentally ill population as a whole, cardiovascular disease is the leading cause of death
across the United States.8
Higher Mortality Due to Drug Use
A mortality rate refers to the rate of death among a population. Countless
studies and reviews illustrate that SMI sufferers exhibit a notably higher mortality rate as
compared to the general population; one 2009 study found that SMI patients in public
hospitals and mental centers lose about 25 to 30 years of potential life,9 while another
review estimated that they die, on average, 15 to 20 years earlier than those without
SMI.10
Additionally, sudden cardiac death rate doubles among users of first-generation
antipsychotics, such as haloperidol, and users of second-generation antipsychotics, like
quetiapine.11 Virtually all patients that present with SMI take oral antipsychotics,
especially the more modern second-generation antipsychotics, either continuously or
at some point in life due to their efficacy and tolerability.12 Multiple studies have
established this conspicuously increased risk of cardiovascular death, and the gap is
ever widening.13 In fact, approximately 60% of the premature mortality among SMI
patients is due to physical illness alone, particular causes being coronary heart disease,
atherosclerosis, hypertension, and stroke, which are all metabolically related.14 Not
including suicide, other leading causes of death include respiratory diseases, diabetes,
and cancer.15
What are antipsychotics?
Antipsychotics are typically psychiatrists' first choice for treating mental illnesses
that deal with psychosis or related episodes, particularly schizophrenia and bipolar
Kahl, Westhoff-Bleck, and Krüger, "Effects of Psychopharmacological Treatment with Antidepressants on the Vascular System," 11.
Ward and Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," 523.
Ibid.
8 Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," 30.
9 Ibid.
10 Kahl, Westhoff-Bleck, and Krüger, "Effects of Psychopharmacological Treatment with Antidepressants on the Vascular System," 11.
11 Ward and Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," 527.
12 Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," 32-33.
13 Ward and Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," 527.
14 Kahl, Westhoff-Bleck, and Krüger, "Effects of Psychopharmacological Treatment with Antidepressants on the Vascular System," 11.
15 Kahl, Westhoff-Bleck, and Krüger, "Effects of Psychopharmacological Treatment with Antidepressants on the Vascular System," 11.
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disorder.16 Essentially, antipsychotics work to terminate and prevent psychosis and
related episodes, such as bipolar mania.17 The beginning of first-generation
antipsychotics, otherwise known as typical antipsychotics, dates back to the 1950s. The
more commonly used second-generation antipsychotics, also called atypical
antipsychotics, achieved FDA approval in the 1990s.18 Due to the ability of
antipsychotics to subdue episodes of mental illness to a homeostatic level, they are an
essential part of the psychiatrist's toolkit, and an essential part of the therapeutic
regimen for SMI. And, like all drugs on the market, antipsychotics have the potential to
cause adverse side effects. What differentiates antipsychotics from other drugs,
however, is the great capacity of cardiovascular risk that comes along with them. In a
2012 review of studies targeting adverse side effects, second-generation antipsychotics
were found to frequently cause weight gain, insulin resistance, dyslipidemia (high
cholesterol), type II diabetes, and hypertension. What's more is that they did so much
more significantly than first-generation antipsychotics.19 As Newcomer points out in a
2009 paper on safety and efficacy of atypical antipsychotics, "Individual antipsychotic
medications are associated with different levels of risk for adverse effects on body
weight and body fat […] In general, as adiposity increases, so does risk for dyslipidemia,
hypertension, and hyperglycemia, conditions that all contribute to the risk of
[cardiovascular disease]."20 In other words, although antipsychotics in the general sense
are more than likely to cause an increase in body fat, which subsequently leads to
serious cardiovascular risk factors, certain individual antipsychotics pose a much
greater risk than others. Ziprasidone, fluphenazine, and haloperidol are three examples
of antipsychotics associated with relatively low risk of weight gain.21 Conversely,
researchers attribute significant weight increases to the more commonly used secondgeneration antipsychotics clozapine and olanzapine. Unfortunately, these two are also
the ones that seem to offer the greatest therapeutic effect. Clozapine, though linked
with the most weight gain as compared to other antipsychotics, has been termed the
'gold standard treatment' for patients with treatment-resistant schizophrenia, as its
antipsychotic effects are statistically paramount to the effects of other antipsychotics
on treatment resistant types.22
It seems as if the key problem in the modern psychiatric school of thought lies in
the guideline of Western medicine: identify the source of illness and treat it with drugs.
This is exactly the function that antipsychotics play in those with SMI – they subdue
acute psychotic or manic episodes and can also prevent them. It is the logical
framework of psychiatric therapy, and exactly why psychiatrists prefer to prescribe
clozapine and the like. However, with such a therapeutic framework, comorbidities
arise. Instead of holistically approaching therapeutics by taking a patient's physical risk
factors into account, the standard American psychiatrist targets isolated mental
disorders and treats them respectively. Unfortunately, this does not mimic the
interrelated systems of the body, which affect one another.23
Siegfried Kasper, "The Metabolic Syndrome and Antipsychotic Treatment," Annals of General Psychiatry 7, (2008): 1,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=35703860&site=ehost-live.
Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," 32.
18 "A History of Atypical Antipsychotics," USA Today (May 2, 2006): 5a,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=J0E075503181706&site=ehost-live.
19 Pavo Filaković, Anamarija Petek Erić, and Ljiljana Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," Medicinski Glasnik 9,
no. 2 (2012): 181, http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=79820876&site=ehost-live.
20 Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," 32.
21 Ibid., 33.
22 Ibid.
23 Shiv Gautam, "Fourth Revolution in Psychiatry - Addressing Comorbidity with Chronic Physical Disorders," Indian Journal of Psychiatry 52, no. 3 (Jul,
2010): 213, http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=54556866&site=ehost- live.
16
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Case Study: Obesity and Antipsychotic Use
In a 2012 study of body mass index and obesity of SMI patients, being overweight
or obese was statistically very common in the sample. Additionally, "prescription of
antipsychotics was associated with obesity and the total percentage dose of
antipsychotic correlated with BMI."24 Essentially, this finding supports the notion that,
assuming those prescribed with antipsychotics are indeed taking them, not only are the
drugs themselves correlated with BMI, but the correlation is dose dependent. In this
particular case, the higher the dose of antipsychotics, the higher the patient's BMI.
But what about causation? Was it the antipsychotic medications themselves that
caused the greater BMI of the sample, or were there more factors at play that directly
affected BMI? For this study and many others, the answer remains unclear. What the
results seem to show, however, is the presence of factors, other than psychotropic
medications, at play. The 2012 study mentioned, "antipsychotic medication, poor diet,
and a lack of motivation to exercise," were important contributory factors to the high
prevalence of overweight and obese subjects.25 Moreover, the mental health
community saw mortality from all causes in schizophrenic patients double between the
1970s and the 1990s, key decades for antipsychotic introduction.26
What is metabolic syndrome?
Metabolic syndrome is a clustered diagnosis that encompasses obesity,
hypertension, impaired glucose-tolerance, and dyslipidemia. Due to its constituents,
metabolic syndrome is a risk factor for type II diabetes, cardiovascular disease, and
cardiovascular related death. The incidence for metabolic syndrome increases with
increase in adiposity, meaning that overweight or obese patients are especially at risk.27
How do antipsychotics cause metabolic syndrome?
Psychotropic drugs as a whole may influence weight gain, "through increased
food consumption and disruption of satiety signaling system."28 Many times, weight gain
is directly caused by second-generation antipsychotics. They can cause fat distribution
to concentrate around the abdomen, which, in turn, is a direct cause for insulin
resistance, the hallmark of type II diabetes. Since type II diabetes is a well-established
risk factor for cardiovascular disease and cardiovascular related death, what is
illustrated with antipsychotic drug use is a train of cause and effect with a sour final
destination. In fact, the correlations between antipsychotics, metabolic disease, and
diabetes are so distinct that the FDA (Federal Food and Drug Administration) asked the
producers of second-generation antipsychotics to include a warning on the label of
their products. This warning specifies the need for blood sugar tests before treatment
and in regular intervals throughout. The American Diabetes Association has similarly
published a consensus outlining the higher risks for obesity, type II diabetes, and
dyslipidemia associated with some antipsychotics. The Association found the
antipsychotics with the highest risk to be clozapine and olanzapine, while those with the
24 C. Haw and S. Bailey, "Body Mass Index and Obesity in Adolescents in a Psychiatric Medium Secure Service," Journal of Human Nutrition and
Dietetics: The Official Journal of the British Dietetic Association 25, no. 2 (2012): 167,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db= cmedm&AN=21585567&site=ehost-live.
25 Ibid.
26 Ibid.
27 Kasper, "The Metabolic Syndrome and Antipsychotic Treatment," 1.
28 Filaković, Erić, and Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," 180.
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lowest risk are ziprasidone and aripriprazole.29 In one study of 95 severely mentally ill
patients, 100% of patients on a clozapine regimen were overweight or obese, and
approximately 90% of the patients on an olanzapine regimen had a raised BMI. The
study concluded that clozapine and olanzapine both have the inclination to cause
meaningful weight gain in a dose-dependent manner.30 As aforementioned, clozapine
is coincidentally the antipsychotic considered to be the 'gold standard' treatment for
hard-to-treat types,31 and since this is often the case for those with SMI, the prescription
of clozapine may be a critical factor in the mortality rate of the SMI population. A
particular marker from another study shows that the weight gain resultant from
antipsychotic use increases exponentially from the start of treatment and does not
reach plateau until several weeks or months from the onset, supporting the causation
argument.32 Furthermore, according to Haw and Bailey, the extra weight gained is not
prone to come off: "at least 70% of obese adolescents will remain obese as adults,"33
and the mere presence of obesity in adolescence can cause serious physical
comorbidities like diabetes, cardiovascular disease, and cancer. This sequence forges
the direct link between adolescent obesity and increased mortality in adulthood.34
Antipsychotics can directly cause weight gain by interfering with signals in the
brain that tell the body the stomach is full, more than likely leading to overeating.
Additionally, antipsychotics can directly reduce the intensity of physical activity by the
same mechanism.35 One such hormone that plays a role in appetite is leptin. Treatment
with antipsychotics of high metabolic risk, such as clozapine and olanzapine, can
cause a drug-induced resistance to leptin, which indicates satiation to the brain. This
phenomenon explains the event that circulating leptin levels double at the onset of
treatment with both clozapine and olanzapine, suggesting that the body is not using
the leptin in the bloodstream to signal the brain – a drug-induced leptin resistance.
Some researchers hypothesize that since leptin and insulin are "mutually coupled in this
system,"36 it is possible that the antipsychotics themselves affect insulin in the same way,
making insulin resistance potentially independent of weight gain for some patients.37
Other scientific reviews claim that this hypothesis is indeed accepted fact, as insulin
dysfunction in those taking clozapine and olanzapine has occurred in patients of a
healthy weight, healthy clinical trial volunteers, and animal models.38
How do antipsychotics increase the risk of diabetes?
Two risk factors for diabetes, dyslipidemia and increased insulin resistance, have
the potential to be direct effects of some psychotropic drugs; antipsychotics can cause
insulin resistance even without weight gain as the causal factor.39
The role of insulin is the distinctive feature in type II diabetes. The body secretes
insulin to regulate blood sugar level, which is usually raised during digestion. An
absence of insulin allows blood sugar levels to spike, while insulin secretion lowers blood
sugar levels by storing the sugar in the liver or as body fat. The hormone can also
Ibid., 180-184.
Haw and Bailey, "Body Mass Index and Obesity in Adolescents in a Psychiatric Medium Secure Service," 169-170.
31 Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," 33.
32 Filaković, Erić, and Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," 181.
33 Haw and Bailey, "Body Mass Index and Obesity in Adolescents in a Psychiatric Medium Secure Service," 169-170.
34 Ibid., 169.
35 Filaković, Erić, and Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," 184.
36 Ibid.
37 Ibid.
38 Katrina Weston-Green, Xu-Feng Huang, and Chao Deng, "Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic
M3 Receptor," CNS Drugs 27, no. 12 (2013): 1071,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=24114586&site=ehost-live.
39 Filaković, Erić, and Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," 180-184.
29
30
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reduce food intake by interacting with insulin receptors in various parts of the brain,
reducing the urge to eat.40
Because drugs like clozapine and olanzapine can increase the peripheral
resistance to insulin, these and antipsychotics like these can directly cause diabetes. 41
Peripheral resistance to insulin refers to the decreased ability or complete inability of
peripheral tissues, meaning muscle and fat, to absorb sugar from the blood.42
One specific hormone receptor that some antipsychotics react with, termed
'M3R,' has been identified as, "a predictor of antipsychotic diabetogenic liability."43 M3R
also has a relationship with weight gain. Accumulated results from several studies show
that acetylcholine muscarinic receptors – M3R, for example – play important roles in the
pathology of SMI and antipsychotic drug efficacy. The affinity of metabolically high risk
second-generation antipsychotics (e.g., clozapine and olanzapine) to bind to M3R
receptor sites is high, while second-generation antipsychotics that exhibit low M3R
binding affinity (e.g., risperidone, ziprasidone, aripiprazole) have much lower adverse
metabolic effects. This trend reflects the high M3R binding affinity of a first-generation
antipsychotic called chlorpromazine, a foreshadowing of the drug's 'diabetogenic
effect.'44
Stop the flow of antipsychotics?
From a clinical standpoint, it is fair to say that SMI sufferers need their
medications, especially following prior psychotropic drug treatment. Sudden cessation
of psychotropic drugs can lead to mild or even life-threatening nervous system
complications and/or psychiatric decompensation.45 For example, in a study of
pregnant women who abruptly stopped their psychotropic drug therapy, as is the
standard protocol during pregnancy, nearly one third of the sample population
experienced suicidal ideation, one of the primary factors that psychotropic drugs aim
to prevent.46 Movement disorders resembling parkinsonism, distinguished by tremors,
and dyskinesias, which impair voluntary movement, may even occur upon cessation.47
With these risks in mind, vacating antipsychotic treatment completely is not the solution
to the mortality gap from a clinical standpoint.
Cost implications of SMI treatment
Due to the complexity and largely unknown pathology of SMIs like schizophrenia
and bipolar disorder, treatment costs among the population are burdensome to the
U.S. healthcare system. From a policy perspective, this poses an economic problem
that suggests reform, especially since mental health care in general accounts for about
10% of U.S. Medicaid costs; as of 2013, schizophrenia alone cost Medicaid and other
state agencies $21.4 billion.48 Physical comorbidities among SMI sufferers are also
correlated with a substantial increase in economic burden for states. Schizophrenia
patients alone constitute about 10% of the permanently disabled and are therefore
Weston-Green, Huang, and Deng, "Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor," 1071.
Filaković, Erić, and Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," 184.
42 Ibid.
43 Weston-Green, Huang, and Deng, "Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor," 1072.
44 Ibid.
45 Ward, Martha and Ann Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," Journal of
Hospital Medicine 8, no. 9 (2013): 528,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=90096361&site=ehost-live.
46 Ibid., 524
47 Ward and Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," 525.
48 Zachary S. Predmore, Soeren Mattke, and Marcela Horvitz-Lennon, "Improving Antipsychotic Adherence among Patients with Schizophrenia:
Savings for States," Psychiatric Services (Washington, D.C.) 66, no. 4 (2015): 343,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=25555222&site=ehost-live.
40
41
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dependent on sources of public assistance.49 Not only does physical comorbidity
compound the treatment costs of SMI patients through adverse cardiovascular events
that often lead to costly hospitalizations or tertiary care – it also increases the likelihood
that these individuals will be absent in the labor force and unable to help provide for
family members such as their children.50 Withdrawal from these areas of economic
contribution often leads to an even greater cost for the state to financially provide for
SMI sufferers and their families.
In order to troubleshoot for healthcare cost issues, it is necessary to review cost
analyses and specify expensive components of care for this population. Having SMI,
and being actively treated for it, has been found to increase the risk of obesity,
cardiovascular disease, and diabetes. Another factor that compounds the cost
problem is the finding that while the addressed physical comorbidities are more
prevalent in the SMI population, patients are less likely to report them and clinicians are
less likely to treat them, posing a primary care discrepancy.51 In particular, screening
rates for obesity and weight-related metabolic disorders is low.52 When cardiometabolic
conditions such as hypertension are left untreated, adverse events that require costly
hospitalizations are more likely to occur. In another cohort study of 67,862 bipolar
sufferers in a managed care population, patients taking second-generation
antipsychotics alone had an estimated 24% higher cost than the general population,
while those taking both mood stabilizers and second-generation antipsychotics, which
is the most prominent case for bipolar sufferers, posed an estimated 52% higher
healthcare cost. For bipolar sufferers, the key cost components included inpatient care
(31%), outpatient visits (16%), prescription drugs (24%), and physician encounters (16%).
However, though prescription drug costs and doctor visits were among the most
expensive cost components, merely 33% of total treatment costs were specific to
bipolar disorder. Instead, the remaining 67% of the costly healthcare provided to
bipolar sufferers was allocated for the treatment of comorbidities. To boot, each
comorbidity identified individually had a noteworthy impact on cost: there was not an
outlier skewing the data.53 Similarly, cost components for the treatment of schizophrenia
comprise much more than the direct costs of inpatient psychiatric care and related
pharmacotherapy. Although patients diagnosed with schizophrenia make up only 1%
of the population, costs to treat them accumulate to 2.5% of the U.S. health care
expenditure.54 The annual treatment cost of schizophrenia is similar to the cost of
treating coronary artery disease across the whole population.55 Based on these results
and results of various studies on the cost breakdown of healthcare for those with SMI,
efforts to control cost must logically target the comorbidities that arise in concurrence
with SMI as well as the use of other avenues that can limit hospitalizations.

Implementing Collaborative Care to Manage Costs
49 M. Seshamani, "Is Clozapine Cost-Effective? : Unanswered Issues," European Journal of Health Economics 3, (2002):
104, http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=15205453&site=ehost-live.
50 A-La Park, David McDaid, Prisca Weiser, Carolin Von Gottberg, Thomas Becker, and Reinhold Kilian, "Examining the Cost Effectiveness of
Interventions to Promote the Physical Health of People with Mental Health Problems: A Systematic Review," BMC Public Health 13, no. 1 (2013): 2,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=90248116&site=ehost-live.
51 Ibid., 1.
52 Ibid.
53 Jeff J. Guo, Jr Keck Paul E., Hong Li, Raymond Jang, and Christina M. L. Kelton, "Treatment Costs and Health Care Utilization for Patients with Bipolar
Disorder in a Large Managed Care Population," Value in Health 11, no. 3 (May, 2008): 419-421,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=32073797&site=ehost-live.
54 Seshamani, "Is Clozapine Cost-Effective? : Unanswered Issues," 104-106.
55 Ibid.
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The increased cardiovascular risk factors and related adverse events among SMI
patients relative to the general population is acknowledged by health care providers
and researchers. Additionally, policy makers have identified the costly public
consequence. Both primary care physicians and psychiatrists face obstacles in the
treatment of the SMI population. While general practitioners lack a deep knowledge
about the psychiatric features and treatment options for SMI sufferers, psychiatrists lack
insight and expertise in managing physical comorbidities that are commonly linked with
SMI treatment.56 To combat the problem, policy makers and researchers worldwide
have teamed up in hopes of finding a resolution. In an important Cochrane review, the
Collaborative Care model demonstrated clinical efficacy as well as cost-effectiveness
in over 80 randomized controlled trials.57
Collaborative Care is an evidence-based model of care that integrates the
mental and behavioral health aspects of psychiatry with the primary care setting. In the
Collaborative Care health care model, clinicians with concentrations in mental,
behavioral, and primary care are team members and take a team-based approach to
treating the SMI patient. To implement the collaborative care model, the care team
must adhere to four principles: patient-centered team care, population-based care,
measurement-based treatment to target, and evidence-based care.58
•Invitations for health
checks using patient
registry

•Lifestyle interventions
•Primary care
•Psychiatry
•Behavioral Health
managers (nurses)

Patientcentered
Team Care

Evidencebased
Care
•Pharmacological
management of SMI with
higher adherence
•LAI antipsychotics

Populationbased
Care

Measurement-

based
Treatment
to Target

•Metabolic screening:
•BMI
•Hypertension
•Cholesterol
•Fasting blood glucose
•Prolactin

59

56 Anne Looijmans, Frederike Jörg, Richard Bruggeman, Robert Schoevers, and Eva Corpeleijn, "Design of the Lifestyle Interventions for Severe
Mentally Ill Outpatients in the Netherlands (LION) Trial; a Cluster Randomised Controlled Study of a Multidimensional Web Tool Intervention to Improve
Cardiometabolic Health in Patients with Severe Mental Illness," BMC Psychiatry 17, (2017): 2,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=afh&AN=122365452&site=ehost-live.
57 Christina Mangurian, Grace C. Niu, Dean Schillinger, John W. Newcomer, James Dilley, and Margaret A. Handley, "Utilization of the Behavior
Change Wheel Framework to Develop a Model to Improve Cardiometabolic Screening for People with Severe Mental Illness," Implementation
Science: IS 12, no. 1 (2017): 2,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=29137666&site=ehostlive.
58 Ibid.
59 Ibid., 5.
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Patient-Centered Team Care
Lifestyle interventions
Lifestyle interventions in the SMI population are critical, as these patients are less
likely to access primary care than the general population.60 Particular lifestyle behaviors
that are negatively affected by incidence of SMI are lower levels of autonomous
motivation towards physical activity, unhealthy diet, non-adherence to medication
regimens, poor hygiene, and inadequate maintenance of physical health conditions.61
Given the troublesome high level of metabolic disease and associated risk for
premature death in those with SMI, implementation of lifestyle interventions to tackle
the diet, exercise, hygiene, and maintenance of physical disease are of utmost
importance.62
In a UK study in which researchers interviewed SMI patients as part of a lifestyle
intervention program, there seemed to be a preliminary belief among patients that
they were healthy and did not need to immediately confront the risk factors that they
possessed. For instance, one interviewee stated that since their doctor performs a
yearly blood test review, he or she did not need additional attention paid to risk
factors.63 When asked if smoking cessation may prevent further stroke, another patient
stated, “No – I don’t really think it does – no.”64 Similarly, another interviewee failed to
understand the link between dietary salt intake and high blood pressure. These
examples demonstrate the lack of general health knowledge and lack of urgency to
change that clinicians need to address among the population via lifestyle interventions.
Additionally, participation in a lifestyle intervention is maximized when the initial
approach is made by each patient’s caseworker. Another UK editorial poses that when
patients are admitted to the hospital, mental health services should use the time frame
as a window to recommend and explain participation in a lifestyle intervention.65
In a Dutch study of SMI patients, lifestyle interventions were shown to be effective
for both weight loss and reduction in cardiometabolic risk factors like high blood sugar
and cholesterol levels.66 In the Dutch model, the three key components of lifestyle
interventions include exercise, diet, and behavior. Appointments per patient should be
made on a weekly or nightly basis for up to six months with a nurse in a primary care or
community health setting.67 Psychiatric nurses and therapists use behavioral therapy
strategies to improve self-management skills such as goal setting and creation of action
60 Robert Pearsall, Susan Hughes, John Geddes, and Anthony Pelosi, "Understanding the Problems Developing a Healthy Living Programme in Patients
with Serious Mental Illness: A Qualitative Study," BMC Psychiatry 14, no. 1 (2014): 3,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=94426984&site=ehost-live.
61 Looijmans, Anne, Frederike Jörg, Richard Bruggeman, Robert Schoevers, and Eva Corpeleijn, "Design of the Lifestyle Interventions for Severe
Mentally Ill Outpatients in the Netherlands (LION) Trial; a Cluster Randomised Controlled Study of a Multidimensional Web Tool Intervention to Improve
Cardiometabolic Health in Patients with Severe Mental Illness," BMC Psychiatry 17, (2017): 2,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=afh&AN=122365452&site=ehost-live.
62 Ibid., 10.
63 Pearsall, Robert, Susan Hughes, John Geddes, and Anthony Pelosi, "Understanding the Problems Developing a Healthy Living Programme in
Patients with Serious Mental Illness: A Qualitative Study," BMC Psychiatry 14, no. 1 (2014): 6,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=94426984&site=ehost-live.
64 Ibid., 8.
65 Ibid., 8-13.
66 Looijmans, Jörg, Bruggeman, Schoevers, and Corpeleijn, "Design of the Lifestyle Interventions for Severe Mentally Ill Outpatients in the Netherlands
(LION) Trial; a Cluster Randomised Controlled Study of a Multidimensional Web Tool Intervention to Improve Cardiometabolic Health in Patients with
Severe Mental Illness," 2.
67 David Osborn, Alexandra Burton, Rachael Hunter, Louise Marston, Lou Atkins, Thomas Barnes, Ruth Blackburn, et al, "Clinical and Cost-Effectiveness
of an Intervention for Reducing Cholesterol and Cardiovascular Risk for People with Severe Mental Illness in English Primary Care: A Cluster
Randomised Controlled Trial," The Lancet.Psychiatry (2018): 147,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=29396118&site=ehost-live.
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plans.68 Other behavioral measures should include physical activity and diet
questionnaires, which the nurse or behavioral health manager should review.69
The Dutch lifestyle intervention study used key steps to implement lifestyle
interventions. The chart below describes the four most important steps in order.

1.
2.

3.
4.

Lifestyle Intervention Steps70
Identify unhealthy behaviors
Behaviors highly related to health risks
After discussion with the nurse, patient should set three
Create a lifestyle plan
attainable goals. The nurse’s role is to guide realistic goal
setting.
Evaluate goals regularly. During every regular care visit,
Evaluate lifestyle goals
patient and nurse should fill in a new questionnaire to
measure progress.
Nurse should guide patient in discussing what factors
Indicate barriers and
foster goal achievement and what factors inhibit goal
facilitators in achieving goals
achievement.

While the nurse is present to offer guidance during the intervention, the patient
should take leadership in creating a lifestyle plan and setting lifestyle goals. In this way,
each individual patient will be able to tailor the lifestyle intervention to his or her specific
recovery wishes.71
In a similar lifestyle intervention study conducted in the UK, the primary outcome
was reduction in cholesterol levels, and the intervention was associated with fewer
hospital admissions.72 Another study on lifestyle interventions across multiple countries
determined that supervised walking was highly cost effective in a 16-week randomized
trial of a tailored exercise program.73

68 Looijmans, Jörg, Bruggeman, Schoevers, and Corpeleijn, "Design of the Lifestyle Interventions for Severe Mentally Ill Outpatients in the Netherlands
(LION) Trial; a Cluster Randomised Controlled Study of a Multidimensional Web Tool Intervention to Improve Cardiometabolic Health in Patients with
Severe Mental Illness," 2.
69 Osborn, Burton, Hunter, Marston, Atkins, Barnes, Blackburn, et al, "Clinical and Cost-Effectiveness of an Intervention for Reducing Cholesterol and
Cardiovascular Risk for People with Severe Mental Illness in English Primary Care: A Cluster Randomised Controlled Trial," 147.
70 Looijmans, Jörg, Bruggeman, Schoevers, and Corpeleijn, "Design of the Lifestyle Interventions for Severe Mentally Ill Outpatients in the Netherlands
(LION) Trial; a Cluster Randomised Controlled Study of a Multidimensional Web Tool Intervention to Improve Cardiometabolic Health in Patients with
Severe Mental Illness," 8, table 3.
71 Ibid., 10.
72Osborn, Burton, Hunter, Marston, Atkins, Barnes, Blackburn, et al, "Clinical and Cost-Effectiveness of an Intervention for Reducing Cholesterol and
Cardiovascular Risk for People with Severe Mental Illness in English Primary Care: A Cluster Randomised Controlled Trial," 147-150.
73 Park, McDaid, Weiser, Gottberg, Becker, and Kilian, "Examining the Cost Effectiveness of Interventions to Promote the Physical Health of People
with Mental Health Problems: A Systematic Review," 4-8.
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What community
health/psychiatry needs to
change
Who should perform the
behavior
When to perform the
behavior
Where to perform the
behavior

Implement lifestyle interventions

Nurses or other behavioral health managers
When seeing patients that take antipsychotic drugs
At community mental health clinics or primary care offices

How often to perform the
behavior

Annually per patient

For whom should they
perform the behavior

All patients taking antipsychotic drugs

Population-based Care
Invitations for Health checks
It is commonly understood by the general population that physical health
checks should occur at least once a year.74 A contributing factor to why SMI sufferers
have higher levels of cardiovascular death may be due to the fact that they tend to
volunteer symptoms less readily. For this reason, physical comorbidity in the early stages
may go unidentified and unmaintained through the course of the morbidity.75 Evidence
shows that invitations to pre-scheduled health checkups are an intervention method
that is both time conducive and cost effective, and positively affects the rate at which
SMI patients access primary care.76
In an instrumental UK study evaluating SMI patient response to an invitation letter,
70% of the SMI patients invited to a primary care-oriented health checkup attended.
One important discrepancy of the study revealed that letters containing an open
invitation produced a much lower attendance rate (37%) than the 70% attendance
rate produced by invitation letters that indicated a specific date and time for the
health check.77 Another UK study found that 68.3% of those who received invitation
letters attended a health check,78 and yet another study provided that 63.3% of
Misuzu Fujita, Yasunori Sato, Kengo Nagashima, Sho Takahashi, and Akira Hata, "Impact of Geographic Accessibility on Utilization of the Annual
Health Check-Ups by Income Level in Japan: A Multilevel Analysis," PLoS ONE 12, no. 5 (2017): 1-14,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=122942297&site=ehost-live.
75 Richard Gray and Sheila Hardy, "Is the use of an Invitation Letter Effective in Prompting Patients with Severe Mental Illness to Attend a Primary Care
Physical Health Check?," Primary Health Care Research & Development (Cambridge University Press / UK) 13, no. 4 (2012): 347-348,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=84125115&site=ehost-live.
76 Ibid., 350-355.
77 Ibid., 348.
78 Alice S. Forster, Caroline Burgess, Lisa McDermott, Alison J. Wright, Hiten Dodhia, Mark Conner, Jane Miller, Caroline Rudisill, Victoria Cornelius, and
Martin C. Gulliford, "Enhanced Invitation Methods to Increase Uptake of NHS Health Checks: Study Protocol for a Randomized Controlled
74
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patients invited to a health check responded.79 Since age is not a factor that affects
the respondent rate of health check invitation letters, SMI patients of all ages may
benefit from this interventional method. Letters should not be sent to those in inpatient
care, residential care, or prison, as these patients are rotationally seen by health care
professionals. 80
When patients were sent an invitation letter ten days before the pre-scheduled
appointment, 70% attended.81 A short time period between the disposition of the letter
by the office of the physician and acquisition of the letter by the patient is conducive to
patient attendance because of the cognitive problems that often accompany SMI or
are a side effect of a psychotropic medication regimen. One common problem is poor
memory, and consequently, poor planning. If the patient does not attend the health
check, the office should send out an invitation for another appointment. When offices
send a secondary appointment, an additional 4% of patients attend the health check,
reflecting about one sixth of absentees.82
The widespread use of electronic medical records (EMR) by clinicians allows
doctors to easily separate patients with SMI from patients without. This ability makes the
invitation process an easy, quick, and inexpensive intervention method.
Evidence from related sources suggests that specific changes to health-check
invitation letters can critically impact behavioral responses from patients.83 One UK
study conducted in 2016 found that four critical changes to health-check invitation
letters were particularly instrumental in improving patient attendance. The first was
simplification; letters should be shortened to two, one-sentence paragraphs to reduce
time and effort on behalf of the patient. The second change is the use of concrete
statements and specified instructions. Thirdly, the heading of the letter should be
emboldened and state that the intended patient is ‘due to attend’ a health check,
rather than relaying that the patient is ‘invited to attend’ a health-check. The fourth
change is the addition of a tear-off slip for the specified date and time of the
appointment with an instruction for the patient to put the slip on their fridge or calendar
as a reminder. These small, low cost changes to health check invitation letters were
shown to improve patient attendance by 26% as compared to a standard health
check invitation letter.84

Trial," Trials 15, no. 1 (2014): 2,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=110265355&site=ehost-live.
79 Anna Sallis, Amanda Bunten, Annabelle Bonus, Andrew James, Tim Chadborn, and Daniel Berry, "The Effectiveness of an Enhanced Invitation Letter
on Uptake of National Health Service Health Checks in Primary Care: A Pragmatic Quasi-Randomised Controlled Trial," BMC Family Practice 17,
(2016): 2, http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=27009045&site=ehost-live.
80 Gray and Hardy, "Is the use of an Invitation Letter Effective in Prompting Patients with Severe Mental Illness to Attend a Primary Care Physical Health
Check?," 349-350.
81 Ibid., 348.
82 Ibid., 348-349.
83 Sallis, Bunten, Bonus, James, Chadborn, and Berry, "The Effectiveness of an Enhanced Invitation Letter on Uptake of National Health Service Health
Checks in Primary Care: A Pragmatic Quasi-Randomised Controlled Trial," 3.
84 Ibid., 3-7.
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What primary
care/community health
needs to change
Who should perform the
behavior
When to perform the
behavior
Where to perform the
behavior

Send annual health check invitation letters, with specified
day and time
Secretaries or office administration with help of EMR
Ten days before the scheduled appointment
At administrative offices of community mental health
clinics/primary care

How often to perform the
behavior

Annually per patient (about 10-15 times per month given a
typical community psychiatrist’s caseload)

For whom should they
perform the behavior

All patients taking antipsychotic drugs

Measurement-based Treatment to Target
Cardiometabolic screening
Since cardiovascular and metabolic health is a target area for cost
containment, cardiometabolic screening should be one of the most important
measurement-based interventions for SMI patients. Traditionally, physicians screen
patients for cardiovascular and metabolic risk factors at the primary care level.
However, SMI patients are far less likely to utilize primary care than the general
population.85 Instead, the care that SMI patients most commonly access originates from
community mental health services like clinics.86 BMI, blood pressure, glucose and
cholesterol monitoring are additionally recommended.87 In the UK, recommendations
also include tests for liver function and prolactin levels even if symptoms are not
present; prolactin testing is in line with UK bipolar disorder treatment guidelines, since
certain antipsychotics are associated with elevated levels of the hormone, which can
cause breast development in men.88
Other areas that overlap with measurement-based treatment to target include
previously mentioned lifestyle interventions, as they involve goal tracking and
regimented follow up appointments, and annual health checks.
85 Mangurian, Niu, Schillinger, Newcomer, Dilley, and Handley, "Utilization of the Behavior Change Wheel Framework to Develop a Model to Improve
Cardiometabolic Screening for People with Severe Mental Illness," 2.
86 Ibid.
87 Gray and Hardy, "Is the use of an Invitation Letter Effective in Prompting Patients with Severe Mental Illness to Attend a Primary Care Physical Health
Check?," 348.
88 Ibid., 353.
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What psychiatry needs to
change

Regular assessment of metabolic screening rather than
assuming this has been tackled by primary care

Who should perform the
behavior
When to perform the
behavior
Where to perform the
behavior

When seeing patients that take antipsychotic drugs

How often to perform the
behavior

Annually per patient (about 10-15 times per month given a
typical community psychiatrist’s caseload)

For whom should they
perform the behavior

All patients taking antipsychotic drugs

Psychiatrists or nurse practitioners

At community mental health clinics

Evidence-based Care
Regarding the SMI population, policy makers are uncertain of which aspects of
health care to target for cost-containment. Recent efforts by states such as Maine and
New Hampshire have focused on cutting antipsychotic drug costs, a component of
care with high economic burden. However, in an effort to resolve the dilemma,
evidence-based conclusions from many cohort studies and meta-analysis reviews
document that it is the lack of preventive care that leads to costly outcomes, as
adverse medical events require in-patient hospitalizations. Therefore, in order to create
a cost impact on SMI treatment, measures to make severe mental illnesses and their
comorbidities manageable conditions should be the primary focus. Of schizophrenia
treatment costs, about 67% is spent on in-patient care, while pharmacotherapies
encompass only .6%.89 Moreover, due to “financial constraints of government agencies,
health insurance plans, and managed care companies, the investment of resources in
high-cost residential care limits the amount of money that can be put into community
care and pharmacotherapy.”90 This finding paints the picture that states concentrate
their health care dollars on the cheapest antipsychotics that demonstrate efficacy, with
no attention paid to how well patients will adhere to said drugs or how the drugs may
affect or exacerbate the physical condition of the SMI population.
Medicaid cost-containment parameters tailored to second-generation
antipsychotics lead to antipsychotic nonadherence, illustrating a misallocation of state
dollars.91 Because patients present with low adherence rates and high comorbidity
Seshamani, "Is Clozapine Cost-Effective? : Unanswered Issues," 105.
Ibid.
91 William B. Vogt, Geoffrey Joyce, Jing Xia, Riad Dirani, George Wan, and Dana P. Goldman, "Medicaid Cost Control Measures Aimed at SecondGeneration Antipsychotics Led to Less use of all Antipsychotics," Health Affairs (Project Hope) 30, no. 12 (2011): 2346,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=22147863&site=ehost-live.
89
90
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rates when doctors prescribe the cheapest medications, the up-front cost-cutting
measures in pharmacotherapy are actually hurting state economies.
Investing in better adherence for cost-containment
Non-adherence to antipsychotic therapy is the primary reason for relapse and
increased institutionalization in SMI patients. Increase in medication adherence could
yield more than $3.28 billion in net savings.92 Although a medication adherence
initiative projects an 18% increase in prescription drug costs, this increase will be far
outweighed by the fruitful 68% savings from lower hospitalization rates; the rest of the
savings will come from lower costs of outpatient care and lower rates of patient
encounters with the criminal justice system.93
Currently, efforts on the part of state governments and private health insurance
plans focus on imposing prior authorization programs and other controls to stabilize drug
spending. Prior authorization programs guide psychiatrists to prescribe lower-cost
medications before medications that are more-costly to public payers. State
governments have targeted second-generation antipsychotics in particular for prior
authorization due to their high costs and usage rates among patients with Medicaid.94
Between 1999 and 2005, annual spending per Medicaid enrollee on
antipsychotics increased by 106%, net of inflation.95 In concurrence, prior authorization
requirements increased dramatically during the same time frame. What states often
overlook is the effect that such utilization management measures have imposed on
state-funded healthcare costs. The introduction of prior authorization in Maine, for
example, led to antipsychotic nonadherence of 29%.96 Studies in New Hampshire and
Georgia found that implementation of prior authorization, among other restrictions, did
reduce the use of targeted drugs, but effectively increased spending on outpatient
and other health services. In one review, the state Medicaid programs that instituted
prior authorization exhibited “no significant correlation between the imposition of prior
authorization and initial levels of spending,”97 as the use of second-generation
antipsychotics per Medicaid enrollee still rose by 14% between 1999-2008 in these prior
authorization states.98
The obvious deterrent for public payers to increase drug spending is the up-front
expense of investment. Unwillingness to make this investment, however, leads to higher
costs in the end: poor adherence is linked with poorer outcomes and higher treatment
costs.99 Therefore, the long-term cost-effectiveness of moving towards increased drug
spending should offer states an incentive.
Better adherence using LAI antipsychotics
Because non-adherence is a problem, long-acting injectable (LAI)
antipsychotics are a treatment option that incentivizes adherence and subsequently
lowers healthcare expenditures. LAIs offer a treatment alternative for patients with
Predmore, Mattke, and Horvitz-Lennon, "Improving Antipsychotic Adherence among Patients with Schizophrenia: Savings for States," 343-344.
Ibid.
94 Vogt, Joyce, Xia, Dirani, Wan, and Goldman, "Medicaid Cost Control Measures Aimed at Second-Generation Antipsychotics Led to Less use of all
Antipsychotics," 2346-2347.
95 Ibid., 2350.
96 Ibid., 2350-2351.
97 Ibid., 2351.
98 Ibid., 2347-2351.
99 Predmore, Mattke, and Horvitz-Lennon, "Improving Antipsychotic Adherence among Patients with Schizophrenia: Savings for States," 343.
92
93
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chronic non-adherence especially.100 LAI antipsychotics do come in generic versions,
and use of generic LAIs in place of oral antipsychotics could lead to a yearly savings of
$1000 per patient in Medicaid programs according to a 2013 study.101 One large cohort
study exhibited that patients who used LAI antipsychotics for more than six consecutive
months experienced less relapses, and consequently less hospitalizations than patients
who used LAIs for a short duration. In addition, patients who only used LAIs for a short
duration had higher rates of comorbidity, logically contributing to more frequent
hospitalizations and their resulting costs.102
LAI therapy generally requires patients to receive an injection every two to six
weeks, completely eliminating the need for oral antipsychotics, which require use one
or more times per day.103 Psychiatrists have the option to administer certain LAI
antipsychotics only once every three months.104 Reducing patients’ maintenance
responsibility through such injections may offer reprieve from relapse and
hospitalizations for sufferers of SMI. For instance, studies report that when bipolar
disorder remains untreated due to non-adherence, the relapse rate exceeds 90% for
manic episodes and 70% for depressive episodes. Not only have LAIs been shown to
reduce risk of antipsychotic cessation in cohort studies, but they also can ensure a more
stable blood level of the antipsychotic than an oral version.105 According to
researchers, psychiatrists should target LAI antipsychotic treatment at young, recently
diagnosed SMI patients, as they pose the highest risk of antipsychotic non-adherence
that contributes to healthcare costs.106
Though physicians introduced LAI antipsychotics into routine clinical practice
decades ago, they are widely underutilized when compared to oral antipsychotics; in a
2007 study of LAI antipsychotic use, only 10% of Medicaid insured patients used them.107
Some authors hypothesize that the unpopularity may be due to lack of awareness of
LAIs as a treatment option or unwillingness to increase medication costs by public
payers.108 Negative patient attitudes towards LAIs are likely due to insufficient
information given by physicians, suggesting that educating patients about LAI
antipsychotics as a treatment option will increase positive patient attitudes.109
In a survey of psychiatrists and SMI patients across Australia, Canada, and the
United States, physicians reported preference for switching to LAIs from oral
antipsychotics for the treatment of both adherent and non-adherent patients, even if
efficacy would be reduced as much as 9% for the switch to once-monthly LAIs, and as
much as 21% for the switch to LAIs lasting three months.110 As oral antipsychotic
Thomas R. Einarson, Colin Vicente, Roman Zilbershtein, Charles Piwko, Christel Bø N., Hanna Pudas, Rasmus Jensen, and Michiel E. H. Hemels,
"Pharmacoeconomics of Depot Antipsychotics for Treating Chronic Schizophrenia in Sweden," Nordic Journal of Psychiatry 68, no. 6 (2014): 417,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=24274837&site=ehost-live.
101 Predmore, Mattke, and Horvitz-Lennon, "Improving Antipsychotic Adherence among Patients with Schizophrenia: Savings for States," 344.
102 Rimal Bera, Steve Offord, Donna Zubek, Gina Lau, Jay Lin, and Craig Karson, "Hospitalization Resource Utilization and Costs among Medicaid
Insured Patients with Schizophrenia with Different Treatment Durations of Long-Acting Injectable Antipsychotic Therapy," Journal of Clinical
Psychopharmacology 34, no. 1 (2014): 33,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=24135840&site=ehost-live.
103 Ibid., 30.
100

105 Gokay Alpak, Bahadir Demir, Ihsan Aksoy, Hilal Kaya, Ahmet Unal, Feridun Bulbul, and Haluk A. Savas, "Both Typical and Atypical Long-Acting
Injectable Antipsychotics in Bipolar Disorder: A Retrospective Chart Review," Journal of Mood Disorders 4, no. 1 (2014): 21,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=95402041&site=ehost-live.
106 Dominic Pilon, Erik Muser, Patrick Lefebvre, Rhiannon Kamstra, Bruno Emond, and Kruti Joshi, "Adherence, Healthcare Resource Utilization and
Medicaid Spending Associated with Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotic Treatment among Adults Recently
Diagnosed with Schizophrenia," BMC Psychiatry 17, (2017): 15,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=123430672&site=ehost-live.
107 Bera, Offord, Zubek, Lau, Lin, and Karson, "Hospitalization Resource Utilization and Costs among Medicaid Insured Patients with Schizophrenia with
Different Treatment Durations of Long-Acting Injectable Antipsychotic Therapy," 30-34.
108 Pilon, Muser, Lefebvre, Kamstra, Emond, and Joshi, "Adherence, Healthcare Resource Utilization and Medicaid Spending Associated with OnceMonthly Paliperidone Palmitate Versus Oral Atypical Antipsychotic Treatment among Adults Recently Diagnosed with Schizophrenia," 15.
109 Alpak, Demir, Aksoy, Kaya, Unal, Bulbul, and Savas, "Both Typical and Atypical Long-Acting Injectable Antipsychotics in Bipolar Disorder: A
Retrospective Chart Review," 24.
110 Eva G. Katz, Brett Hauber, Angie Fairchild, Srihari Gopal, Rachel B. Weinstein, Bennett S. Levitan, and Amy Pugh, "Physician and Patient Benefit-Risk
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adherence decreased, physician preference for LAIs increased, and physicians would
accept higher possible reductions in efficacy that could come along with the
medication switch.111 Physicians also reported a preference for LAIs that they need only
administer once every three months for patients with a history of skipping between 20%50% of doses. Patients reported preference for LAI antipsychotics for use in nonadherent patients.112
One particular LAI antipsychotic, ‘paliperidone palmitate’ (PP1M or PP-LAI) is a
once-monthly second-generation LAI antipsychotic that is associated with greater
patient adherence levels, lower polypharmacy, reduced frequency of home care
services, and lower overall medical costs as compared to treatment with oral secondgeneration antipsychotics.113 Administration dates are flexible in an effort to avoid
missed monthly doses; physicians may administer PP-LAI 7 days before or after the
exact monthly mark.114 In a 2014 Swedish study comparing the cost-effectiveness of
both first and second-generation antipsychotics, PP-LAI was shown to have the lowest
per-patient cost for institutional care, suggesting that the greater adherence that LAIs
impose on SMI patients directly causes less institutionalizations.115 In the same study, the
cost driver for the SMI patients sampled was institutionalization, comprising 52.5%-80.7%
of care, depending on the antipsychotic treatment regimen.116 Although the costeffectiveness of the LAI ‘risperidone’ (RIS-LAI) is reasonably comparable to the cost
effectiveness of PP-LAI, PP-LAI is paramount due to its longer duration of action, which
allows administration to be much less frequent. With fewer administrations, missing a
dose is less probable, which supports patient adherence.117 Switching from oral
paliperidone palmitate to PP-LAI is easy as well – treatment with PP-LAI can safely begin
1 day after stopping oral PP. When switching from a different LAI antipsychotic,
physicians may administer PP-LAI in place of the next scheduled injection.118

Discussion
Episodes of severe mental illness (SMI) are characterized by breaks from reality,
among other symptoms that vary according to the diagnosis. Bipolar disorder and
schizophrenia are the two most prevalent SMIs. Due to the severity of symptoms and
adverse side effects from antipsychotic drug treatment, patients of this population
often depend on the public health care system to pay for their medical care, which,
per patient, far exceeds the healthcare expenditure as compared to that of the
general population.
Antipsychotic drugs may either directly or indirectly cause metabolic disease
and increase cardiovascular risk factors and cardiovascular related death. Because
antipsychotic drugs are a necessary part of the treatment regimen for SMI patients,
Preferences from Two Randomized Long-Acting Injectable Antipsychotic Trials," Patient Preference & Adherence 10, (2016): 2131-2134,
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=119302706&site=ehost-live.
111 Ibid.
112 Ibid.
113 Pilon, Muser, Lefebvre, Kamstra, Emond, and Joshi, "Adherence, Healthcare Resource Utilization and Medicaid Spending Associated with OnceMonthly Paliperidone Palmitate Versus Oral Atypical Antipsychotic Treatment among Adults Recently Diagnosed with Schizophrenia," 14.
114 Mahesh N. Samtani, Srihari Gopal, Cristiana Gassmann-Mayer, Larry Alphs, and Joseph M. Palumbo, "Dosing and Switching Strategies for
Paliperidone Palmitate Based on Population Pharmacokinetic Modelling and Clinical Trial Data," CNS Drugs 25, no. 10 (2011):
840, http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=69849338&site=ehost-live.
115 Einarson, Vicente, Zilbershtein, Piwko, Bø, Pudas, Jensen, and Hemels, "Pharmacoeconomics of Depot Antipsychotics for Treating Chronic
Schizophrenia in Sweden," 422.
116 Ibid.
117 Ibid., 423.
118 Samtani, Gopal, Gassmann-Mayer, Alphs, and Palumbo, "Dosing and Switching Strategies for Paliperidone Palmitate Based on Population
Pharmacokinetic Modelling and Clinical Trial Data," 837.
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psychiatrists – especially those working in community health centers – need to pay
greater attention to the physical condition of the population in an attempt to reduce
the high rate at which SMI sufferers experience cardiovascular morbidity. Conclusions
from a variety of cohort studies and meta-analyses suggest that states implement a
collaborative health care model in which psychiatrists, primary care physicians, and
behavioral health managers (nurses) work together to holistically support the health of
the SMI patient using lifestyle interventions, invitations for annual health checks, and
cardiometabolic screening. These interventions will not only offer room for physical
health improvement and better physical health maintenance, but will also save public
payers money by reducing the encounters that SMI patients have with
institutionalization, hospitalization, tertiary care, and the criminal justice system.
Because institutionalized care is the highest health cost area for the SMI
population, an initial investment on the part of public payers to encourage psychiatrists’
prescribing of long-acting injectable (LAI) antipsychotics will be instrumental in
increasing medication adherence due to the associated low maintenance regimen as
compared to oral antipsychotic therapy. Although injectable antipsychotics will not
directly improve cardiometabolic health, they may offer stabilization of side effects
such as weight gain, since side effects occur the most quantitatively at the onset of
drug therapy. When patients are not consistent with oral antipsychotic therapy, there
are more instances of drug onset, as therapy must be restarted. Higher medication
adherence among SMI patients will lead to less institutionalizations and effectively
reduce the healthcare expenditure for this population. Treatment with paliperidone
palmitate (PP-LAI) in particular offers long-term cost savings for Medicaid programs and
other state agencies.
SMI patients accrue a large portion of expense for public payers due to their
mental illness, cardiometabolic comorbidities, and associated high hospitalization rates.
However, primary care interventions and better drug therapies are available and states
can implement them in a cost-effective manner. Doing so will not only better the
physical health of those with severe mental illness, but will consequently relieve public
health care programs of a substantial part of the population’s heavy health care
burden.
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